{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:06:45Z","timestamp":1791410805450,"version":"4.3.3"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,10,1]]},"DOI":"10.2169\/internalmedicine.5025-24","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T18:15:18Z","timestamp":1742580918000},"page":"2876-2880","source":"Crossref","is-referenced-by-count":1,"title":["Oligogenic Familial Hypercholesterolemia Treated by Combination Therapy of Statin, Ezetimibe, PCSK9 Inhibitor, and Lomitapide"],"prefix":"10.2169","volume":"64","author":[{"given":"Nobuko","family":"Kojima","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Takamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: The Metabolic and Molecular Bases of Inherited Disease. 8th Ed. Scriver CR, Beaudet AL, Sly WS, Valle D, Eds. McGraw-Hill, New York, 2001: 2863e913."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Tada H, Takamura M, Kawashiri MA. Individualized treatment for patients with familial hypercholesterolemia. J Lipid Atheroscler 11: 39-54, 2022.","DOI":"10.12997\/jla.2022.11.1.39"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nohara A, Tada H, Ogura M, et al. Homozygous familial hypercholesterolemia. J Atheroscler Thromb 28: 665-678, 2021.","DOI":"10.5551\/jat.RV17050"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Harada-Shiba M, Arai H, Ohmura H, et al. Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022. J Atheroscler Thromb 30: 558-586, 2023.","DOI":"10.5551\/jat.CR005"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Harada-Shiba M, Ohtake A, Sugiyama D, et al. Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022. J Atheroscler Thromb 30: 531-557, 2023.","DOI":"10.5551\/jat.CR006"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tada H, Fujino N, Nomura A, et al. Personalized medicine for cardiovascular diseases. J Hum Genet 66: 67-74, 2021.","DOI":"10.1038\/s10038-020-0818-7"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Takeji Y, Tada H, Ogura M, et al.; Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labor, and Welfare of Japan. Clinical characteristics of homozygous familial hypercholesterolemia in Japan: a survey using a National Database. JACC Asia 3: 881-891, 2023.","DOI":"10.1016\/j.jacasi.2023.07.011"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Tada H, Kojima N, Yamagami K, et al. Effects of different types of pathogenic variants on phenotypes of familial hypercholesterolemia. Front Genet 13: 872056, 2022.","DOI":"10.3389\/fgene.2022.872056"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tada H, Kawashiri MA, Nomura A, et al. Oligogenic familial hypercholesterolemia, LDL-cholesterol, and coronary artery disease. J Clin Lipidol 12: 1436-1444, 2018.","DOI":"10.1016\/j.jacl.2018.08.006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tada H, Nohara A, Usui S, Sakata K, Kawashiri MA, Takamura M. Impact of the severe familial hypercholesterolemia status on atherosclerotic risks. Sci Rep 13: 19782, 2023.","DOI":"10.1038\/s41598-023-47147-z"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tada H, Okada H, Nohara A, et al. Impact of high-density lipoprotein function, rather than high-density lipoprotein cholesterol level, on cardiovascular disease among patients with familial hypercholesterolemia. Circ J 87: 806-812, 2023.","DOI":"10.1253\/circj.CJ-22-0560"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tada H, Yamagami K, Kojima N, et al. Prevalence and impact of apolipoprotein E7 on LDL cholesterol among patients with familial hypercholesterolemia. Front Cardiovasc Med 8: 625852, 2021.","DOI":"10.3389\/fcvm.2021.625852"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J 44: 2277-2291, 2023.","DOI":"10.1093\/eurheartj\/ehad197"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tada H, Kojima N, Yamagami K, et al. Early diagnosis and treatments in childhood are associated with better prognosis in patients with familial hypercholesterolemia. Am J Prev Cardiol 12: 100434, 2022.","DOI":"10.1016\/j.ajpc.2022.100434"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Luirink IK, Wiegman A, Kusters DM, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med 381: 1547-1556, 2019.","DOI":"10.1056\/NEJMoa1816454"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/19\/64_5025-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:21:53Z","timestamp":1759548113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/19\/64_5025-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":15,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5025-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"article-number":"5025-24"}}